Nosocomial COVID-19 Incidence and Secondary Attack Rates among Patients of Tertiary Care Center, Zurich, Switzerland.

COVID-19 SARS-COV-2 Switzerland coronavirus disease cross-infection infection control infectious disease transmission nosocomial infections risk factors severe acute respiratory syndrome coronavirus 2 viruses zoonoses

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
10 2022
Historique:
pubmed: 2 9 2022
medline: 24 9 2022
entrez: 1 9 2022
Statut: ppublish

Résumé

Of 1,118 patients with COVID-19 at a university hospital in Switzerland during October 2020-June 2021, we found 83 (7.4%) had probable or definite healthcare-associated COVID-19. After in-hospital exposure, we estimated secondary attack rate at 23.3%. Transmission was associated with longer contact times and with lower cycle threshold values among index patients.

Identifiants

pubmed: 36048771
doi: 10.3201/eid2810.220321
pmc: PMC9514341
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2087-2090

Références

Vaccine. 2022 Jan 31;40(5):701-705
pubmed: 34953607
Lancet. 2021 May 1;397(10285):1603-1605
pubmed: 33865497
Clin Infect Dis. 2022 Mar 23;74(6):1097-1100
pubmed: 34145449
Am J Infect Control. 2021 Dec;49(12):1464-1468
pubmed: 34551334
J Hosp Infect. 2020 Nov;106(3):621-625
pubmed: 32841703
Emerg Infect Dis. 2022 Oct;28(10):2134-2137
pubmed: 36001791
Infect Control Hosp Epidemiol. 2021 Jul 12;:1-4
pubmed: 34250882
Clin Infect Dis. 2022 May 3;74(9):1579-1585
pubmed: 34329418
Clin Infect Dis. 2021 Feb 16;72(4):690-693
pubmed: 32562422
Clin Infect Dis. 2021 Jul 30;73(Suppl 2):S138-S145
pubmed: 33045075
Emerg Microbes Infect. 2022 Dec;11(1):1-5
pubmed: 34890524
J Visc Surg. 2020 Jun;157(3S1):S13-S18
pubmed: 32381426
Emerg Microbes Infect. 2022 Dec;11(1):337-343
pubmed: 34935594

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH